Physician profile
Michael Egger
NPI 1689846982
$3,229.56
in general payments reported to CMS, 2019-2025
23 companies · $375 in 2025
The $375 reported for 2025 was more than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $709 · 2020: $299 · 2021: $86.14 · 2022: $756 · 2023: $700 · 2024: $305 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,380.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,374.98 | 2019-2022 | |
| Abbvie INC. | $789.36 | 2021-2025 | Strattice Reconstructive Tissue Matrix Bps, Creon |
| Davol INC. | $349.22 | 2023-2025 | Phasix Mesh, Arista |
| Intuitive Surgical, INC. | $115.46 | 2025 | |
| Amgen INC. | $93.64 | 2019-2021 | |
| Genzyme Corporation | $59.57 | 2020-2021 | |
| Ethicon US, LLC | $54.77 | 2019 | |
| Astellas Pharma US INC | $44.04 | 2023-2024 | Xospata |
| Kerecis Limited | $36.16 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Celgene Corporation | $34.21 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $33.25 | 2019-2020 | |
| Genentech, INC. | $31.64 | 2023 | Tecentriq |
| Avita Medical Americas, LLC | $29.69 | 2025 | Permeaderm, Recell, Cohealyx |
| Merck Sharp & Dohme LLC | $26.73 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $24.77 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mentor Worldwide LLC | $23.83 | 2022 | |
| Incyte Corporation | $23.53 | 2019-2020 | |
| Cerus Corporation | $16.20 | 2023 | Intercept Blood System For Platelets |
| Medical Device Business Services, INC. | $16.18 | 2019 | |
| Medtronic, INC. | $15.63 | 2023 | Emprint |
| Bayer Healthcare Pharmaceuticals INC. | $13.59 | 2020 | |
| Janssen Biotech, INC. | $11.57 | 2020 | |
| Daiichi Sankyo INC. | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Egger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.